In conclusion, we believe that our data open the path to long-term observational studies in individuals with DS to validate the hypothesis that a deficit of TGF-β1 can represent a new biological marker useful to predict AD-related cognitive decline in individuals with DS and monitor the progression and/or development of cognitive decline in its prodromal phase. The gene discussed is TGFB1; the disease is Dravet syndrome.